Male reproductive health

Male Reproductive Health: An In-Depth Study Guide

Table of Contents

1. Testicular Cancer
   1.1. Incidence/Significance
   1.2. Risk Factors
   1.3. Germ Cell Tumors
   1.4. Clinical Manifestations
   1.5. Late Clinical Manifestations

2. Benign Prostatic Hyperplasia (BPH)
   2.1. Definition and Normal Anatomy of the Prostate
   2.2. Risk Factors
   2.3. Etiology of BPH
   2.4. Clinical Manifestations
   2.5. Complications
   2.6. Treatment Options

3. Prostate Cancer
   3.1. Overview
   3.2. Risk Factors
   3.3. Clinical Manifestations
   3.4. Screening and Controversies
   3.5. Prognosis

4. Erectile Dysfunction (ED)
   4.1. Definition and Significance
   4.2. Classification of ED
   4.3. Etiology of Secondary ED
   4.4. Physiology of Normal Erection
   4.5. PDE-5 Inhibitors

5. References

1. Testicular Cancer

1.1. Incidence/Significance

• Testicular cancer represents 1% of all male cancers.

• It is a major cancer found in men aged 15-35 years.

• Testicular cancer is known for being one of the most curable cancers.

1.2. Risk Factors

• Cryptorchidism (undescended testicles)

• Family history

• Caucasian race

• HIV infection

1.3. Germ Cell Tumors

• 95% of testicular cancers are germ cell tumors.

  • Seminomas:

  • Arise from immature germ cells.

  • They are characterized by slow growth and nonaggressive nature.

  • Easily cured with radiation treatment.

  • Nonseminomas:

  • Arise from mature germ cells.

  • More aggressive compared to seminomas.

  • Typically treated surgically.

1.4. Clinical Manifestations

• Early Manifestations:

  • Enlargement of the testicle.

  • Presence of a painless mass (noted in most cases).

  • If discomfort is present (in 30-40% of cases):

  • Dull ache in the groin.

  • Sensation of heaviness in the affected testicle.

1.5. Late Clinical Manifestations

• Possible acute pain.

• Manifestations from metastatic spread:

  • Cough.

  • Hemoptysis (coughing blood).

  • Swelling of lower extremities.

  • Back pain.

  • Dizziness.

2. Benign Prostatic Hyperplasia (BPH)

2.1. Definition and Normal Anatomy of the Prostate

• BPH is a nonmalignant enlargement of the prostate gland, surrounding the urethra.

• The prostate produces seminal fluids and weighs between 4-20 grams.

• Normal structure includes:

  • Gland surrounding the urethra.

  • Functions crucial for male reproductive health.

2.2. Risk Factors

• Non-modifiable Risk Factors:

  • Age.

  • Family history.

  • Race/Ethnicity.

• Modifiable Risk Factors:

  • Obesity and metabolic syndrome.

  • Caffeine consumption.

  • Physical inactivity.

2.3. Etiology of BPH

• Two Theories:

  1. Hormone Imbalance:

  • Involving testosterone and estrogen (estradiol).

  1. DHT Accumulation:

  • DHT (dihydrotestosterone) formation:
    $ext{Testosterone} + 5 ext{ alpha-reductase} <br>ightarrow ext{DHT}$

  • DHT acts on various tissues influencing various physiological changes.

2.4. Clinical Manifestations

• Symptoms include:

  • Frequency and urgency in urination.

  • Increased time to urinate.

  • Dribbling post-urination.

  • Delay in initiating urination.

  • Reduced force of urination.

  • Nocturia (frequent urination at night).

  • Weak urine stream.

  • Inability to completely empty the bladder, leading to urinary tract infections.

2.5. Complications

• Obstruction of urethra.

• Increased risk of urinary tract infections (UTIs).

• Potential renal problems due to obstruction.

2.6. Treatment Options

• Mild Symptoms: Watchful waiting.

• Moderate Symptoms: Initiate drug therapy:

  • 5-alpha reductase inhibitors.

  • Alpha1-adrenergic antagonists.

• Severe Symptoms: Consider invasive options.

5-α-reductase inhibitors

• Finasteride (Proscar):

  • Indication: Mechanical obstruction of urethra.

  • MOA:

  • Blocks conversion of testosterone to DHT.

  • Decreases epithelial tissue in prostate.

  • Effectiveness in newly diagnosed patients depends on baseline prostate size.

  • Results may be observed after several months of therapy.

• Adverse Effects:

  • Impotence (5-10%).

  • Decreased libido.

  • Gynecomastia (breast tissue enlargement).

  • Notably decreases prostate-specific antigen (PSA) levels.

  • Caution in handling due to side effects.

• Dutasteride (Avodart):

  • Similar indications and MOA as finasteride but also affects type 2 DHT receptors.

Alpha1-Adrenergic Antagonists

• Prototype: Tamsulosin (Flomax).

  • MOA:

  • Relaxes smooth muscle cells specifically in the prostate.

  • Indicated for dynamic obstruction of the urethra.

  • Adverse Effects:

  • Generally well tolerated but may cause abnormal ejaculation.

Combination Therapy

• Using Dutasteride + Tamsulosin ( trade name Jalyn).

  • FDA approved for management of BPH.

  • Evidence indicates that combination therapy is more effective than either agent alone.

3. Prostate Cancer

3.1. Overview

• Prostate cancer is the most common male cancer in the U.S.

• It ranks second behind lung cancer regarding cancer-related deaths.

• Incidence varies significantly among races:

  • Highest in African-American men.

  • Lowest in Asians and Native American men.

• Rapid increase in incidence noted after age 50, with over 80% of cases occurring in men older than 65.

3.2. Risk Factors

• Age

• Ethnicity

• Family history or familial tendency

• High-fat diet, which may influence cancer development.

3.3. Clinical Manifestations

• Presentations can range from:

  • Early symptoms resembling BPH.

  • Late manifestations due to metastasis, commonly affecting

  • Bones.

  • Lungs.

• Prognosis is closely dependent on cancer stage at diagnosis.

3.4. Screening and Controversies

• Controversy arises from the balance between the benefits and risks of screening for prostate cancer.

  • Prostate cancer frequently does not become clinically significant.

  • Many patients may die from other causes rather than from prostate cancer.

  • The earlier screening methods, like PSA testing, were not supported by definitive evidence.

3.5. Prognosis

• Prostate cancer does not lead to death in most individuals diagnosed with it.

• It is categorized into low, intermediate, and high-grade forms based on severity determined by:

  • Gleason score: A higher score indicates more aggressive cancer.

  • Tumor volume: Larger tumors correlate with worse outcomes.

  • PSA Level: Elevated and rapidly increasing levels indicate worse prognosis.

  • Number of positive cores on biopsy: More positive cores indicate greater concern.

4. Erectile Dysfunction (ED)

4.1. Definition and Significance

• Erectile Dysfunction, commonly referred to as impotence, is defined as the inability to achieve or sustain an erection sufficient for satisfactory sexual intercourse.

• Over 30 million men in the U.S. are estimated to experience ED, making it a significant public health issue associated with underlying chronic illnesses.

4.2. Classification of ED

• Primary ED:

  • Rare form characterized by lifelong inability to achieve a normal erection.

  • Often associated with severe psychiatric problems or significant vascular trauma early in life.

• Secondary ED:

  • Most common type, with a history of normal erectile function prior to the onset of ED symptoms.

4.3. Etiology of Secondary ED

• Organic Causes:

  • Peripheral vascular disease, including arterial insufficiency, excessive venous drainage, and a sedentary lifestyle as a risk factor.

• Psychogenic Causes:

  • Conditions include depression, anxiety, and performance-related fears.

• Other Causes:

  • Medications like antidepressants and antihypertensives, endocrine issues, trauma from surgeries (e.g., radical prostatectomy), and strained relationships.

4.4. Physiology of Normal Erection

• Sexual arousal triggers an increase in the parasympathetic nervous system (PNS) activity and release of nitric oxide (NO).

• This activates cyclic guanosine monophosphate (cGMP), resulting in:

  • Relaxation of arterial and smooth muscle cells.

  • Increased blood inflow and reduced outflow leading to engorgement and erection.

• PDE-5 (phosphodiesterase type 5) subsequently breaks down cGMP, impacting the erectile function.

4.5. PDE-5 Inhibitors

• Prototype: Sildenafil (Viagra)

  • MOA:

  • Inhibits PDE5, which increases and preserves cGMP levels.

  • Enhances the normal erectile response to sexual stimuli.

  • Indications: Treatment of ED, pulmonary arterial hypertension, and sometimes BPH.

• Timing of Use: Administration is recommended up to 4 hours before sexual activity, with an onset of 30-60 minutes.

• Adverse Effects:

  • Most commonly: Headache (16%), flushing (10%), dyspepsia (7%).

• Cautions:

  • Contraindicated in patients taking nitrates or those with significant cardiovascular disease due to potential hypotensive effects.

5. References

• Thanks to Lynn Kelso DNP, APRN, FCCM, FAANP.

• Capriotti, T. M., & Frizzell, J. P. (2015). Pathophysiology: Introductory concepts and clinical perspectives. FA Davis Company.

• Nickel JC. (2004). Comparison of clinical trials with finasteride and dutasteride. Rev Urol, 6 Suppl 9(Suppl 9): S31–S39.

• Dimitropoulos, K., & Gravas, S. (2016). Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia. Therapeutic Advances in Urology, 8(1), 19-28.

• (Various sources regarding prostate cancer risk factors and epidemiology).

Note: Additional details and imagery have been provided where applicable to enhance understanding.